The Toronto Stock Exchange reports that it has decided to further extend its review of the eligibility of Aptose Biosciences Inc.'s common shares for continued listing for a period of 60 days. For more information, see the TSX bulletin dated Sept. 24, 2025.
© 2026 Canjex Publishing Ltd. All rights reserved.